BCL2 and colorectal carcinoma: Our findings provide the first evidence supporting the selective cytotoxicity of DHME, indicating stronger cytotoxicity of DHME than hispolon, revealing DHME as a proapoptotic agent, and specifying DHME as an inhibitor targeting the WNT/β-catenin–B-cell lymphoma 2 (BCL-2) pro-survival signaling axis to induce CRC cell apoptosis.